Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?   

Are there specific mutations or co-mutations were you would consider use of this agent? 

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at University of Miami Sylvester Comprehensive Cancer Center
I share the same sentiments with @Karen L. Reckamp...
Sign in or Register to read more